Voronoi

310210.KQ

113.51 USD

-0.46

-0.40%

Overview

Last close

113.51 usd

Market cap

2.04B usd

52 week high

123.07 usd

52 week low

21.08 usd

Target price

146.64 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

845.6414

Price/Book Value

60.5563

Enterprise Value

2.01B usd

EV/Revenue

51.1462

EV/EBITDA

-15.8405

Key financials

Revenue TTM

2.42M usd

Gross Profit TTM

2.42M usd

EBITDA TTM

-30.92M usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

37.94M usd

Net debt

N/A usd

About

Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company's products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer. Voronoi, Inc. was founded in 2015 and is based in Incheon, South Korea.